Apellis Pharmaceuticals (APLS) Scheduled to Post Earnings on Wednesday

Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) is scheduled to release its earnings data after the market closes on Wednesday, May 4th. Analysts expect Apellis Pharmaceuticals to post earnings of ($1.35) per share for the quarter.

Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) last issued its earnings results on Monday, February 28th. The company reported ($1.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.54) by ($0.07). During the same period last year, the firm earned $0.93 earnings per share. On average, analysts expect Apellis Pharmaceuticals to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

NASDAQ APLS opened at $46.44 on Wednesday. The company has a debt-to-equity ratio of 0.95, a current ratio of 6.25 and a quick ratio of 6.13. Apellis Pharmaceuticals has a 1 year low of $27.50 and a 1 year high of $73.00. The stock has a market capitalization of $4.94 billion, a PE ratio of -5.20 and a beta of 1.61. The business’s 50-day moving average is $48.67 and its 200 day moving average is $43.67.

A number of research analysts have weighed in on the company. Robert W. Baird increased their target price on Apellis Pharmaceuticals from $83.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, March 16th. Needham & Company LLC restated a “buy” rating and set a $70.00 price target on shares of Apellis Pharmaceuticals in a report on Friday, December 31st. Citigroup reaffirmed a “focus list” rating and set a $81.00 price target on shares of Apellis Pharmaceuticals in a research note on Thursday, March 17th. JPMorgan Chase & Co. raised their target price on shares of Apellis Pharmaceuticals from $66.00 to $69.00 and gave the company an “overweight” rating in a research note on Monday, April 4th. Finally, Roth Capital downgraded Apellis Pharmaceuticals from a “neutral” rating to a “sell” rating and set a $40.00 target price on the stock. in a research note on Wednesday, April 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $70.67.

In other Apellis Pharmaceuticals news, insider Lukas Scheibler sold 3,504 shares of the business’s stock in a transaction dated Monday, April 4th. The stock was sold at an average price of $56.96, for a total transaction of $199,587.84. Following the completion of the transaction, the insider now owns 52,233 shares of the company’s stock, valued at $2,975,191.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Alec Machiels sold 1,250 shares of the business’s stock in a transaction on Tuesday, March 15th. The stock was sold at an average price of $39.57, for a total transaction of $49,462.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 39,399 shares of company stock worth $1,977,305. Corporate insiders own 9.50% of the company’s stock.

A number of institutional investors have recently made changes to their positions in APLS. California State Teachers Retirement System lifted its position in Apellis Pharmaceuticals by 22.6% during the 4th quarter. California State Teachers Retirement System now owns 103,701 shares of the company’s stock valued at $4,903,000 after acquiring an additional 19,084 shares during the period. Alliancebernstein L.P. raised its holdings in Apellis Pharmaceuticals by 1.0% during the fourth quarter. Alliancebernstein L.P. now owns 80,000 shares of the company’s stock valued at $3,782,000 after acquiring an additional 800 shares during the period. Legal & General Group Plc lifted its holdings in shares of Apellis Pharmaceuticals by 19.5% in the fourth quarter. Legal & General Group Plc now owns 69,167 shares of the company’s stock worth $3,270,000 after buying an additional 11,268 shares in the last quarter. Credit Suisse AG boosted its stake in Apellis Pharmaceuticals by 6.5% during the fourth quarter. Credit Suisse AG now owns 63,032 shares of the company’s stock valued at $2,980,000 after buying an additional 3,845 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Apellis Pharmaceuticals by 5.7% in the 4th quarter. The Manufacturers Life Insurance Company now owns 35,949 shares of the company’s stock worth $1,715,000 after buying an additional 1,925 shares during the last quarter. Institutional investors and hedge funds own 82.03% of the company’s stock.

Apellis Pharmaceuticals Company Profile (Get Rating)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

See Also